The company added that the US patent no. 8,618,277, or '277 patent, which includes broad, sequence-independent issued claims on compositions of chemically modified siRNA targeting HBV, was awarded by the US Patent and Trademark Office (USPTO).
According to the company, the McSwiggen patent estate broadly describes chemical modifications of RNAi therapeutics needed to achieve "drug-like" properties in siRNA, the molecules that mediate RNAi. The '277 patent includes claims that are critical for the development of RNAi therapeutics for the treatment of hepatitis B virus (HBV) infection.
RNAi (RNA interference) is a revolution in biology, representing a breakthrough in understanding how genes are turned on and off in cells, and a completely new approach to drug discovery and development. RNAi therapeutics have the potential to treat disease and help patients in a fundamentally new way, concluded the company.
(C)2014 M2 COMMUNICATIONS http://www.m2.com